Please provide your email address to receive an email when new articles are posted on . Adults with acromegaly who responded to treatment with an oral form of the somatostatin analogue octreotide ...
CAM2029 is an investigational ready-to-use, long-acting octreotide subcutaneous injection depot. Polycystic liver disease is a rare genetic disorder characterized by the progressive growth of more ...
This was a 48-week, international, open-label, prospective trial of octreotide LAR. Eligible participants were aged 18–80 years with a biochemical diagnosis of acromegaly. Patients who had already ...
The primary goal of depot somatostatin-analogue (SSA) therapy for acromegaly is to reduce disease activity by suppressing growth hormone (GH) and insulin-like growth factor-I (IGF-I) secretion. A test ...
Credit: Getty Images. The NETTER-2 trial included patients with newly diagnosed SSTR-positive, Grade 2 and 3, advanced gastroenteropancreatic neuroendocrine tumors. First-line treatment with lutetium ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. As Healio previously reported, more than 90% of ...
A phase I trial of weekly topotecan and carboplatin in potentially platinum sensitive ovarian and peritoneal carcinoma No significant financial relationships to disclose. This is an ASCO Meeting ...
Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom ...
October 12, 2012 (Montreal, Quebec) — In a finding described as both surprising and practice-changing, octreotide (Sandostatin, Novartis) showed no benefit over less expensive, more accessible ...
May 29, 2012 (Florence, Italy) — In patients with acromegaly, long-acting-release (LAR) pasireotide (SOM230, Novartis) was more effective than octreotide LAR (Sandostatin, Novartis) at inducing ...
(RTTNews) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), announced the launch of the first and only generic version of Sandostatin LAR Depot, in the United States.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback